Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
Public ClinicalTrials.gov record NCT00294762. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Study of Tarceva (Erlotinib) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With Newly Diagnosed Advanced Non-small Cell Lung Cancer Who Have Tumors With EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Study identification
- NCT ID
- NCT00294762
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 143 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2006 (Type not available)
- Primary completion
- Mar 2009 (Actual)
- Completion
- Mar 2009 (Actual)
- Last update posted
- Aug 9, 2012
2006 – 2009
United States locations
- U.S. sites
- 38
- U.S. states
- 20
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Hematology Oncology Medical Group Inc. | Alhambra | California | 91801 | — |
| Comprehensive Blood and Cancer Center(Part of TORI network) | Bakersfield | California | 93309 | — |
| Bay Area Cancer Research Group | Concord | California | 94520 | — |
| Virginia K. Crosson Cancer Center | Fullerton | California | 92835 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813-3244 | — |
| UCLA Medical Center | Los Angeles | California | 90095-7077 | — |
| North Valley Hematology/Oncology Medical GroupThe Thomas and Dorothy Leavey Cancer Center | Northridge | California | 91325 | — |
| Ventura County Hematology-Oncology Specialists | Oxnard | California | 93030 | — |
| Wilshire Oncology Medical GroupThe Robert and Beverly Lewis Family Cancer Care Center | Pomona | California | 91767 | — |
| Cancer Care Associates Medical Group, Inc. | Redondo Beach | California | 90277 | — |
| Sansum Santa Barbara Medical Foundation Clinic | Santa Barbara | California | 93105 | — |
| Santa Barbara Hematology Oncology Medical Group, Inc. | Santa Barbara | California | 93105 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer CenterResearch Department | Denver | Colorado | 80218 | — |
| Eastern Connecticut Hematology and Oncology Associates | Norwich | Connecticut | 06360-2910 | — |
| MD Anderson Cancer Ctr - Orlando | Orlando | Florida | 32806 | — |
| Gulfcoast Oncology Associates | Tampa | Florida | 33614 | — |
| Suburban Hematology-Oncology Associates | Lawrenceville | Georgia | 30045 | — |
| Central Georgia Cancer Care, P.C. | Macon | Georgia | 31201 | — |
| Rush-Presbyterian-St.Luke's Med Ctr | Chicago | Illinois | 60612 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Norton Healthcare, Inc. | Louisville | Kentucky | 40202 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Univ. of Minnesota Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Hematology Oncology Centers of Northern Rockies Research | Billings | Montana | 59101 | — |
| Alegent Healthcare | Omaha | Nebraska | 68124 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89052 | — |
| Hematology-Oncology Associates, SJ, PA - Virtua Health | Mount Holly | New Jersey | 08060 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Pottsville Cancer Clinic | Pottsville | Pennsylvania | 17901 | — |
| Boston Baskin Cancer Groupd/b/a U. of Tennessee Cancer Inst. | Memphis | Tennessee | 38104 | — |
| The West Cancer Clinic | Memphis | Tennessee | 38120 | — |
| ACORN | Memphis | Tennessee | 38138 | — |
| University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| Fletcher Allen Health Care | Burlington | Vermont | 05401 | — |
| Cancer Specialists of Tidewater, Ltd. | Chesapeake | Virginia | 23320 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00294762, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2012 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00294762 live on ClinicalTrials.gov.